2021
DOI: 10.1101/2021.04.08.21255148
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents

Abstract: Importance: Alpha-1-adrenergic receptor antagonists (α1-blockers) can abrogate pro-inflammatory cytokines and may improve outcomes among patients with respiratory infections. Repurposing readily available drugs such as α1-blockers could augment the medical response to the COVID-19 pandemic. Objective: To evaluate the association between α1-blocker exposure and COVID-19 mortality Design: Real-world evidence study Setting: Patient level data with 32,355 records tested for SARS-CoV-2 at the Mount Sinai Healt… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…Prior work indicates that certain alpha-1 adrenergic receptor antagonists (alpha blockers) disrupt cytokine storm syndromes, a pathological hyperinflammatory response associated with respiratory infection and other diseases (Staedtke et al, 2018;Koenecke et al, 2021;Thomsen et al, 2021). Subsequently, others determined that hyperinflammation is implicated in morbidity and mortality in COVID-19 patients (Mehta et al, 2020;Li et al, 2021). Many COVID-19 patients were already taking alpha blockers prior to infection for unrelated, chronic medical conditions.…”
Section: Covid-19 Studymentioning
confidence: 99%
“…Prior work indicates that certain alpha-1 adrenergic receptor antagonists (alpha blockers) disrupt cytokine storm syndromes, a pathological hyperinflammatory response associated with respiratory infection and other diseases (Staedtke et al, 2018;Koenecke et al, 2021;Thomsen et al, 2021). Subsequently, others determined that hyperinflammation is implicated in morbidity and mortality in COVID-19 patients (Mehta et al, 2020;Li et al, 2021). Many COVID-19 patients were already taking alpha blockers prior to infection for unrelated, chronic medical conditions.…”
Section: Covid-19 Studymentioning
confidence: 99%